Showing 6651-6660 of 8690 results for "".
- Ortho Dermatologics Announces Aspire Higher Scholarship Honoreeshttps://practicaldermatology.com/news/ortho-dermatologics-announces-aspire-higher-scholarship-honorees/2457972/Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or fou
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- Gut Microbiome May Affect How Metastatic Melanoma Responds to Immunotherapyhttps://practicaldermatology.com/news/gut-microbiome-may-affect-how-metastatic-melanoma-responds-to-immunotherapy/2457986/The gut microbiome can influence how metastatic melanoma responds to immunotherapy, researchers from The University of Texas MD Anderson Cancer Center report in the journal
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Dermatomyositis Breakthrough? Drug reduces disease burden in patients with skin-predominant DMhttps://practicaldermatology.com/news/dermatomyositis-breakthrough-drug-reduces-disease-burden-in-patients-with-skin-predominant-dm/2457990/A new treatment for dermatomyositis (DM) may reduce the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsyl
- Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studieshttps://practicaldermatology.com/news/abbvies-risankizumab-performs-well-in-three-phase-three-psoriasis-studies/2457991/Top-line results from three pivotal Phase 3 clinical trials show that risankizumab, an investigational interleukin-23 (IL-23) inhibitor,
- Chris Greta Appointed Chief Creative Officer at eRelevancehttps://practicaldermatology.com/news/chris-greta-appointed-chief-creative-officer-at-erelevance/2457996/Chris Greta has been appointed as the first chief creative officer for
- Long-Term Fat Reduction Seen Following Treatment with BTL Vanquish, Vanquish MEhttps://practicaldermatology.com/news/long-term-fat-reduction-seen-following-treatment-with-btl-vanquish-vanquish-me/2457992/Abdominal fat reduction achieved via BTL Vanquish and Vanquish ME lasts for at least four years, according to new long-term data released by the company. Both devices use radiofrequency (RF) energy to reduce fat. The study evaluated 13 in
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- FDA Approves Janssen's Golimumab for PsA, AShttps://practicaldermatology.com/news/fda-approved-jansens-golimumab-for-psa-as/2457998/The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF